Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company, issued a shareholder letter from CEO Steven Quay highlighting progress in 2023. Four Phase 2 trials of (Z)-endoxifen are underway, with primary data expected in the second half of the year. The Karisma-Endoxifen trial for breast density reached full enrollment. A federal law effective September 10 will require mammography facilities to notify patients about breast density. Atossa also initiated research with Weill Cornell Medicine on triple-negative breast cancer (TNBC). The company has a strong balance sheet with $94 million in cash as of September 30, 2023, and extended its share repurchase program through December 31, 2024.